Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02
Rhea-AI Summary
Armata Pharmaceuticals (NYSE American: ARMP) reported multiple milestones supporting the planned Phase 3 superiority study of AP-SA02, its intravenous multi-phage candidate for adjunct treatment of complicated Staphylococcus aureus bacteremia caused by MSSA or MRSA. The company submitted the complete Phase 3 protocol and comprehensive responses to all U.S. FDA comments from the End-of-Phase 2 meeting, covering clinical, Chemistry, Manufacturing and Controls, and regulatory topics. Armata also completed four engineering runs of AP-SA02 at its in-house cGMP facility in Los Angeles, with production of Phase 3 clinical trial material as the next step. In June 2026, Armata received an additional $2.5 million continuation award from the U.S. Department of Defense, bringing total funding under this award to $28.7 million to support Phase 3 preparations. The pivotal trial remains on track to initiate in the second half of 2026 and is intended to support a future BLA. The company promoted David House to Chief Financial Officer to support late-stage development and strategy execution.
Positive
- $2.5 million additional DoD funding, total award now $28.7 million
- Completed four AP-SA02 engineering runs at in-house cGMP facility
- Submitted complete Phase 3 superiority protocol and FDA comment responses
- Phase 3 AP-SA02 study targeted to initiate in H2 2026
- Positive Phase 2a diSArm results for AP-SA02 previously reported
- Appointment of new Chief Financial Officer to support strategy execution
Negative
- None.
Market reaction after Phase 3 readiness update: ARMP +12.20% in the Jul 20 session
In the Jul 20 session, ARMP gained 12.20%, reflecting a significant positive market reaction. Argus tracked a peak move of +10.2% during that session. Argus tracked a trough of -5.3% from its starting point during tracking. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Clinical trial Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 07 | Fast Track designation | Positive | +1.0% | FDA granted Fast Track designation for AP-SA02 ahead of planned Phase 3 development. |
| Jan 13 | Phase 3 planning | Positive | -4.9% | FDA confirmed Phase 2a data supported advancing AP-SA02 into a Phase 3 study. |
| May 19 | Phase 2 clinical data | Positive | +75.6% | Positive topline diSArm results reported improved clinical outcomes versus best available antibiotic therapy. |
| May 01 | DoD trial funding | Positive | -15.4% | Additional non-dilutive DoD funding supported the ongoing AP-SA02 diSArm clinical trial. |
| Dec 19 | Phase 2 clinical data | Positive | +1.5% | Tailwind Phase 2 results showed reduced Pseudomonas aeruginosa levels and generally mild adverse events. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Clinical-trial-related announcements produced mixed reactions, with three aligned positive responses and two divergences.
Key Terms
cmc regulatory
cgmp technical
qidp regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
FDA submissions address all feedback on clinical, CMC, and regulatory topics from the End-of-Phase 2 meeting
Four AP-SA02 engineering runs completed; clinical trial material production is the next planned manufacturing step
Phase 3 superiority study remains on track to initiate in the second half of 2026
Recent milestones include submission of the complete Phase 3 protocol and comprehensive responses to all comments received from the
Recent Regulatory and Operational Progress
- Submitted the complete Phase 3 superiority protocol to the FDA for AP-SA02, incorporating all comments received in the End-of-Phase 2 ("EOP2") meeting written response.
- Submitted complete responses to all FDA comments on clinical, Chemistry, Manufacturing, and Controls, ("CMC") and regulatory topics raised in the EOP2 meeting written response.
- Completed four engineering runs of AP-SA02 at the Company's in-house cGMP manufacturing facility in
Los Angeles, CA. Production of clinical trial material to support the planned Phase 3 clinical study is the next planned manufacturing step.
Department of Defense (DoD) Award
The
Separate from the existing or any new DoD award, the Company continues to pursue and evaluate other funding pathways to support the execution of the planned Phase 3 clinical study.
"Advancing AP-SA02 into a Phase 3 superiority study in complicated S. aureus bacteremia remains our top priority," said Dr. Deborah Birx, Chief Executive Officer of Armata. "These submissions move us closer to that goal, and we are focused on initiating a rigorously designed and operationally efficient study to support a future Biologics License Application and potential registration."
Executive Leadership Update
Armata also announced the promotion of David House to Chief Financial Officer. Mr. House has served as the Company's Senior Vice President, Finance and Principal Financial Officer since August 2024. The appointment ensures Armata has the right financial leadership in place to execute on its strategy and advance its clinical programs through late-stage development.
About AP-SA02
Armata is developing AP-SA02, a fixed multi-phage cocktail, for the adjunct treatment of complicated Staphylococcus aureus bacteremia caused by methicillin-sensitive S. aureus (MSSA) or methicillin-resistant S. aureus (MRSA). AP-SA02 has received Qualified Infectious Disease Product (QIDP), and Fast Track designations from the FDA. The diSArm study (NCT05184764) was a Phase 1b/2a, multicenter, randomized, double-blind, placebo-controlled, multiple ascending dose escalation study of the safety, tolerability, and efficacy of intravenous AP-SA02 in addition to best available antibiotic therapy ("BAT") compared to BAT alone (placebo) for the treatment of adults with complicated S. aureus bacteremia. Positive results from the Phase 2a diSArm study were highlighted in a late-breaking oral presentation at IDWeek 2025™ in October 2025. The Company plans to advance AP-SA02 into a Phase 3 superiority study in complicated S. aureus bacteremia, anticipated to initiate in the second half of 2026.
About Armata Pharmaceuticals, Inc.
Armata is a late clinical-stage biotechnology company focused on the development of high-purity pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, S. aureus, and other important pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage-specific current Good Manufacturing Practices ("cGMP") manufacturing to support full commercialization.
Forward Looking Statements
This communication contains "forward-looking" statements as defined by the Private Securities Litigation Reform Act of 1995. These statements relate to future events, results or to Armata's future financial performance and involve known and unknown risks, uncertainties and other factors which may cause Armata's actual results, performance or events to be materially different from any future results, performance or events expressed or implied by the forward-looking statements. In some cases, you can identify these statements by terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" or the negative of those terms, and similar expressions. These forward-looking statements reflect management's beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this communication and are subject to risks and uncertainties including risks related to Armata's development of bacteriophage-based therapies; Armata's planned clinical trials; ability to staff and maintain its production facilities under fully compliant cGMP; ability to meet anticipated milestones in the development and testing of the relevant product; ability to be a leader in the development of phage-based therapeutics; ability to achieve its vision, including improvements through engineering and success of clinical trials; ability to successfully complete preclinical and clinical development of, and obtain regulatory approval of its product candidates and commercialize any approved products on its expected timeframes or at all; and Armata's estimates regarding anticipated operating losses, capital requirements and needs for additional funds. Additional risks and uncertainties relating to Armata and its business can be found under the caption "Risk Factors" and elsewhere in Armata's filings and reports with the U.S. Securities and Exchange Commission (the "SEC"), including in Armata's Annual Report on Form 10-K, filed with the SEC on March 25, 2026, and in its subsequent filings with the SEC.
Armata expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Armata's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Media Contacts:
At Armata:
Pierre Kyme
ir@armatapharma.com
310-665-2928
Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
212-915-2569
i Department of Defense (DoD) award received through the Medical Technology Enterprise Consortium (MTEC) and managed by the Naval Medical Research Command (NMRC) – Naval Advanced Medical Development (NAMD) with funding from the Defense Health Agency and Joint Warfighter Medical Research Program.
View original content to download multimedia:https://www.prnewswire.com/news-releases/armata-pharmaceuticals-achieves-key-progress-across-clinical-regulatory-and-manufacturing-activities-supporting-planned-phase-3-initiation-of-ap-sa02-302829265.html
SOURCE Armata Pharmaceuticals, Inc.